Friday, June 3, 2022

New Options for HIV positive patients treatment will be available soon for daily dose of ART in HIV positive patients treatment

Treatment of HIV positive patients requires daily dose of ART (Antiretroviral Therapy) medicines which are a combination of many anti-retroviral drugs combined together. Combination ART drugs prescribed to HIV positive patients to keep their viral load under control and are very effective in providing protection against HIV to patients.

Daily dose of antiretroviral medicines also has some side effects like  ART related hyperlipidemia and heart diseases ( Cardiovascular effect) nausia and so on, because of which many patients discontinue ART. which is a major reason for development of more complex, serious HIV infection.
Inorder to provide a solution to this, Broadly neutralising Antibody (bNAb) treatment is explored, in a study it is found that if more than two Broadly neutralising antibodies are given to patients in initial stage monthly once and ART is skipped, patients HIV viral load is kept under control, result of protection is similar to ART treatment, therefore this combination of broadly neutralising Antibodies provide an option to long tern ART treatment and relief from the side effects of ART.
Broadly neutralising antibodies do not pose any side effects as they are required to be taken only once in a month as compared to ART which is required to be taken daily.
Anthony S. Fauci, M.D., NIAID director and chief of NIAID’s Laboratory of Immunoregulation and Michael C. Sneller, M.D., and Tae-Wook Chun, Ph.D., also of NIAID’s have conducted the study and found that the patients who do not have antibody resistant HIV virus load in their body can opt for this treatment. Patients have to take once a month infusion of a cocktail of Broadly neutralising Antibody (bNAb). These patients need not take ART drugs.
In future this approach which will have more Broadly neutralising Antibody (bNAb) targeting as many sites on viral particles will be available and this will be one of best option for treatment of HIV positive patients.

No comments: